Q3 EPS Estimates for Nuvation Bio Cut by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Investment analysts at HC Wainwright lowered their Q3 2025 EPS estimates for shares of Nuvation Bio in a research note issued on Thursday, January 23rd. HC Wainwright analyst R. Burns now expects that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $0.73 million during the quarter.

NUVB has been the subject of several other reports. Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a research note on Monday, January 6th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $8.20.

Nuvation Bio Stock Performance

NYSE NUVB opened at $2.52 on Monday. The firm has a market cap of $846.47 million, a price-to-earnings ratio of -1.16 and a beta of 1.47. Nuvation Bio has a one year low of $1.52 and a one year high of $4.16. The firm has a 50 day simple moving average of $2.74 and a 200-day simple moving average of $2.79.

Institutional Trading of Nuvation Bio

A number of large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. acquired a new stake in shares of Nuvation Bio during the third quarter worth $2,790,000. Dimensional Fund Advisors LP increased its position in Nuvation Bio by 415.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock worth $2,975,000 after purchasing an additional 820,669 shares during the period. Wexford Capital LP lifted its holdings in shares of Nuvation Bio by 930.2% in the 3rd quarter. Wexford Capital LP now owns 651,767 shares of the company’s stock valued at $1,493,000 after buying an additional 588,500 shares during the period. FMR LLC boosted its stake in shares of Nuvation Bio by 1.4% in the third quarter. FMR LLC now owns 29,238,871 shares of the company’s stock valued at $66,957,000 after buying an additional 416,932 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Nuvation Bio by 479.1% during the third quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock worth $1,014,000 after buying an additional 366,429 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.